Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells

Carcinogenesis

Volumn 34, Issue 4, 2013, Pages 864-873

  Sehrawat, Anuradha ^a   Kim, Su Hyeong ^a   Vogt, Andreas ^a   Singh, Shivendra V ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL ISOTHIOCYANATE; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXQ1; UNCLASSIFIED DRUG; UROKINASE; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CHEMOPROPHYLAXIS; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANIMALS; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; ISOTHIOCYANATES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84875962938     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs397     Document Type: Article

References (48)

1. Jemal,A. et al.. (2010) Cancer statistics, 2010. CA. Cancer J. Clin., 60, 277-300.
2. Alvarez,R.H. (2010) Present and future evolution of advanced breast cancer therapy. Breast Cancer Res., 12 Suppl 2, S1.
3. Higgins,M.J. et al.. (2011) Breast cancer in 2010: novel targets and therapies for a personalized approach. Nat. Rev. Clin. Oncol., 8, 65-66.
4. Hulka,B.S. et al.. (1995) Breast cancer: cause and prevention. Lancet, 346, 883-887.
5. Zhang,Y. et al.. (1997) Bone mass and the risk of breast cancer among postmenopausal women. N. Engl. J. Med., 336, 611-617.
6. van Zitteren,M. et al.. (2011) Genome-based prediction of breast cancer risk in the general population: a modeling study based on meta-analyses of genetic associations. Cancer Epidemiol. Biomarkers Prev., 20, 9-22.
7. Fisher,B. et al.. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst., 90, 1371-1388.
8. Cauley,J.A. et al.. (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat., 65, 125-134.
9. Goss,P.E. et al..; NCIC CTG MAP.3 Study Investigators. (2011) Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med., 364, 2381-2391.
10. Obiorah,I. et al.. (2011) Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas, 70, 315-321.
11. Boccardo,F. et al.. (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann. Oncol., 17 (suppl. 7), vii10-14.
12. Surh,Y.J. (2003) Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer, 3, 768-780.
13. Stan,S.D. et al.. (2008) Bioactive food components and cancer risk reduction. J. Cell. Biochem., 104, 339-356.
14. Wattenberg,L.W. (1977) Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J. Natl. Cancer Inst., 58, 395-398.
15. Sugie,S. et al.. (1993) Inhibitory effects of benzyl isothiocyanate and benzyl thiocyanate on diethylnitrosamine-induced hepatocarcinogenesis in rats. Jpn. J. Cancer Res., 84, 865-870.
16. Okazaki,K. et al.. (2002) Simultaneous treatment with benzyl isothiocyanate, a strong bladder promoter, inhibits rat urinary bladder carcinogenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine. Nutr. Cancer, 42, 211-216.
17. Kuroiwa,Y. et al.. (2006) Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. Cancer Lett., 241, 275-280.
18. Warin,R. et al.. (2009) Prevention of mammary carcinogenesis in MMTVneu mice by cruciferous vegetable constituent benzyl isothiocyanate. Cancer Res., 69, 9473-9480.
19. Thiery,J.P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2, 442-454.
20. Tomaskovic-Crook,E. et al.. (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res., 11, 213.
21. Hollier,B.G. et al.. (2009) The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mammary Gland Biol. Neoplasia, 14, 29-43.
22. Sehrawat,A. et al.. (2011) Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells. Cancer Prev. Res. (Phila)., 4, 1107-1117.
23. Warin,R. et al.. (2010) Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate. Mol. Carcinog., 49, 500-507.
24. Xiao,D. et al.. (2008) Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J. Biol. Chem., 283, 30151-30163.
25. Jo,M. et al.. (2010) Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. Cancer Res., 70, 8948-8958.
26. Zhang,H. et al.. (2011) Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res., 71, 1292-1301.
27. Hahm,E.R. et al.. (2011) Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS ONE, 6, e23354.
28. Xiao,D. et al.. (2003) Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis, 24, 891-897.
29. Xiao,D. et al.. (2006) Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction. Clin. Cancer Res., 12, 6836-6843.
30. Guo,Y. et al.. (2002) Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J. Biol. Chem., 277, 41571-41579.
31. Livak,K.J. et al.. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
32. Boreddy,S.R. et al.. (2011) Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin. Cancer Res., 17, 1784-1795.
33. Hajra,K.M. et al.. (2002) The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res., 62, 1613-1618.
34. Batlle,E. et al.. (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol., 2, 84-89.
35. Lester,R.D. et al.. (2007) uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol., 178, 425-436.
36. Kwaan,H.C. et al.. (2009) The role of plasminogen-plasmin system in cancer. Cancer Treat. Res., 148, 43-66.
37. Qiao,Y. et al.. (2011) FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Res., 71, 3076-3086.
38. Kaneda,H. et al.. (2010) FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res., 70, 2053-2063.
39. Lai,K.C. et al.. (2010) Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J. Agric. Food Chem., 58, 2935-2942.
40. Kim,E.J. et al.. (2012) Benzyl isothiocyanate inhibits basal and hepatocyte growth factor-stimulated migration of breast cancer cells. Mol. Cell. Biochem., 359, 431-440.
41. Aguirre Ghiso,J.A. (2002) Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene, 21, 2513-2524.
42. Liu,D. et al.. (2002) EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell, 1, 445-457.
43. Kjoller,L. et al.. (2001) Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol., 152, 1145-1157.
44. Nusrat,A.R. et al.. (1991) An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. Clin. Invest., 87, 1091-1097.
45. Kim,S.H. et al.. (2011) Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis, 32, 359-367.
46. Ho,C.C. et al.. (2011) Benzyl isothiocyanate (BITC) inhibits migration and invasion of human gastric cancer AGS cells via suppressing ERK signal pathways. Hum. Exp. Toxicol., 30, 296-306.
47. Gulhati,P. et al.. (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res., 71, 3246-3256.
48. Xiao,D. et al.. (2012) Benzyl isothiocyanate causes FoxO1-mediated autophagic death in human breast cancer cells. PLoS ONE, 7, e32597.